$MRK #ASCO20 Plenary Session to Feature Phase 3 Data for KEYTRUDA® (pembrolizumab) in MSI-H/dMMR Colorectal Cancer

New Long-Term Data with KEYTRUDA  More than 15 Tumor Types Including Triple-Negative Breast Cancer, Classical Hodgkin Lymphoma, Non-Small Cell Lung Cancer, RCC